TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02312414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Canitine
Description: Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
Study: NCT02907060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical cervical ripening
Description: The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological cervical ripening
Description: The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics
Study: NCT00361504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR
Description: Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503) ER
Description: Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
Study: NCT04613804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Qualified subjects will be treated with toripalimab 240mg q21d as a treatment cycle.
Study: NCT02256956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg / day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25 mg / day for 10 days
Study: NCT01369732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
Study: NCT03851432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin plus metformin
Description: Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Janagliflozin plus metformin
Description: Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus metformin
Description: Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
Study: NCT04138043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is 0.9 percent sodium chloride solution. It will be administered as SC injection to abdomen by study personnel. Three injections will be used to match active doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection 150 mg/mL.
Study: NCT03282500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
Study: NCT01892124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Cognitive Behavioral-based Therapy
Study: NCT01770015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sampling blood
Description: HLA DR antigen, cytokines (IL 6 and 10), B-glucan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal aspiration
Description: fungi and bacteria endotracheal aspiration
Study: NCT04166617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: conventional physcial therapy rehabilitation for the upper limb

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap motion plus conventional therapya
Description: leap motion plus conventional physcial therapy rehabilitation for the upper limb
Study: NCT01500902

Intervention type: OTHER
Group type: OTHER
Intervention: EndoPAT testing (non invasive device)
Description: Using the EndoPAT device, we will assess endothelial function.

Intervention type: OTHER
Group type: OTHER
Intervention: WatchPAT testing (non-invasive device)
Description: Using the WATCHPAT device we will assess sleep apnea.
Study: NCT03170193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 529
Description: Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of matching placebo by SC or IV injection
Study: NCT01700153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy
Description: This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical therapy
Description: conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical therapy
Description: conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
Study: NCT03273309

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibratory Perineal Stimulus
Description: Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
Study: NCT02256956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg / day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg / day for 10 days
Study: NCT03273309

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal Electrical Stimulation
Description: The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
Study: NCT01301859

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TIP
Description: Treatment visits as usual with MD

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TIP
Description: Treatment visits as usual with MD
Study: NCT00238238

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT02861638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Video of the exercises

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: video of nature scenes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study: NCT02727920

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy drink
Study: NCT02727920

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo drink
Study: NCT03673163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
Study: NCT03413059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Thoracic Epidural morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: thoracic epidural triamcinolone acetonide
Study: NCT01818063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04014452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
Study: NCT03171012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower limbs CRT
Description: cycle ergometer for lower limbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limbs CRT
Description: cycle ergometer for lower limbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limbs CRT
Description: cycle ergometer for upper limbs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limbs CRT
Description: cycle ergometer for upper limbs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiration
Description: respiration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiration
Description: respiration
Study: NCT01910428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase encapsulated in RBC
Description: * 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV
Study: NCT02893085

Intervention type: BIOLOGICAL
Intervention: bile sample analysis
Description: tumor mutation profile tumor genotype

Intervention type: BIOLOGICAL
Intervention: biochemical markers, VEGF and MMPs, in bile samples

Intervention type: BIOLOGICAL
Intervention: biochemical markers, VEGF and MMPs, in bile samples
Study: NCT02054338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine+Gemcitabine
Description: Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel+Gemcitabine
Description: paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
Study: NCT01342510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study: NCT00556244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling
Description: ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
Study: NCT01342510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
Study: NCT01818063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04225793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eziklen®
Description: The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: The Moviprep® solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Moviprep® solution should be completed at least 2 hours and no later than 4 hours before the procedure.
Study: NCT01085292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
Study: NCT02193308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Study: NCT04283591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Acupuncture Treatment Group will get acupuncture treatment which will be applied to Baihui (DU20), Yintang (EX-HN3) points of the hemiplegic side and bilateral Tai Chong (LR3), Hegu (LI4) points for 4 weeks, twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation Programme
Description: They will continue to receive the conventional rehabilitation programme.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Rehabilitation Programme
Description: They will continue to receive the conventional rehabilitation programme.
Study: NCT03458689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left hemicolectomy, laparoscopic technique
Description: Left hemicolectomy, Laparoscopic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left hemicolectomy, laparoscopic technique
Description: Left hemicolectomy, Laparoscopic technique

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Left hemicolectomy, laparoscopic technique
Description: Left hemicolectomy, Laparoscopic technique
Study: NCT04219644

Intervention type: DEVICE
Group type: OTHER
Intervention: Breatheasy device
Study: NCT02110264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Description: Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XR-NTX+PN
Description: In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Participants assigned to the ETAU group will receive drug education.
Study: NCT05084092

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy (IORT)
Description: If biopsy is positive, local treatment with IORT will be performed. After IORT (15,40 Gray at 2 mm dept), the applicator will be removed and surgery will be continued in a standard fashion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain surgery
Description: Surgery should be performed according to the local standard of care, preferentially as image-(neuronavigation) guided surgery. To establish the diagnosis of a metastasis and to exclude primary CNS tumors, lymphomas, SCLCs or germinomas it will be performed a peroperative biopsy
Study: NCT02207218

Intervention type: DRUG
Intervention: turoctocog alfa
Description: No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
Study: NCT02409771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECIZON Presbyopic
Description: Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
Study: NCT01793883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Laninamivir Octanoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80 mg Laninamivir Octanoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04087239

Intervention type: OTHER
Intervention: HIV
Study: NCT02058992

Intervention type: DRUG
Intervention: Ramelteon
Description: Ramelteon 8 mg tablets
Study: NCT01793883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02191813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seresis®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03068767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT04414566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil
Description: Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil
Description: Patients receive GP gemcitabine (1000 mg/m\^2 d1,8) and cisplatin (80mg/m\^2 d1) or TPF docetaxel (60mg/m\^2 on day 1), cisplatin (60mg/m\^2 on day 1) and fluorouracil (600mg/m\^2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m\^2 every 3 weeks for 3 cycles.
Study: NCT04112394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anesthetic injection
Description: A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard perioperative and postoperative analgesia protocol.
Description: Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
Study: NCT02724527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavosonstat
Description: CFTR modulator that stabilizes CFTR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo capsule
Study: NCT00584454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q Fever Vaccine (NDBR 105
Description: Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.